



UNIVERSITI PUTRA MALAYSIA

***EFFECT OF PROBIOTIC LACTOBACILLUS CASEI SHIROTA STRAIN
ON AFLATOXIN B1 LEVEL IN AFLATOXIN-INDUCED RATS***

ELHAM NIKBAKHT NASRABADI

FPSK (m) 2013 41

**EFFECT OF PROBIOTIC *LACTOBACILLUS CASEI* SHIROTA STRAIN ON
AFLATOXIN B₁ LEVEL IN AFLATOXIN-INDUCED RATS**

By

ELHAM NIKBAKHT NASRABADI

**Thesis submitted to School of Graduate Studies, Universiti Putra Malaysia, in
fulfilment of the requirement of the Degree of Master of Science**

February 2013

DEDICATIONS

This thesis is dedicated to my beloved husband, who has been a great source of inspiration and motivation,

To my dear father and mother who have supported me all the way since the beginning of my study,

And to all my friends and families who have believed my abilities, and helped me to make some of my dreams come true.



Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirement for the degree of Master of Science

EFFECT OF PROBIOTIC *LACTOBACILLUS CASEI* SHIROTA STRAIN ON AFLATOXIN B₁ LEVEL IN AFLATOXIN-INDUCED RATS

By

ELHAM NIKBAKHT NASRABADI

February 2013

Chair: Rosita Binti Jamaluddin, PhD

Faculty: Medicine and Health Sciences

Aflatoxin B₁ (AFB₁) is considered as the most toxic food contaminant with harmful impact on human and animal health produced by *Aspergillus* species of fungi namely *Aspergillus flavus* (*A. flavus*) and *Aspergillus parasiticus* (*A. parasiticus*). It is classified as group one carcinogen by the International Agency for Research on Cancer that is linked to the etiology of liver cancer. Intervention and intercession approaches concentrate on pre-and post-harvest measures to reduce AFB₁ levels in crops or on the individual level to modulate bioactivation and excretion of AFB₁ or reduce its bioavailability. Microorganisms, especially bacteria, have been studied for their potential to reduce the bioavailability of aflatoxins as well as other food contaminants. Among them, *lactic acid bacteria* are known to have the ability to reduce the bioavailability of aflatoxins *in vitro*.

This research aims to investigate the effect of probiotic *Lactobacillus casei* Shirota strain (LcS) on AFB₁ level in aflatoxin induced rats through the weight, liver and kidney function tests, and also AFB₁ blood serum level based on two separate studies

of acute and chronic aflatoxicosis. Finally a comparison was done to observe the effect of probiotic LcS supplementation in different duration in acute and chronic exposure to AFB₁. To achieve this purpose, an experimental study was conducted, and a total of 48 animals were divided into two groups (n=24) to conduct two studies of acute and chronic aflatoxicosis. Animals in acute aflatoxicosis experiment were divided into three subgroups of A_a, B_a, and untreated control (n=6). Group A_a (n=9) received LcS (10⁸ CFU) by oral gavage daily for 7 successive days, and group B_a (n=9) received medium which was normal saline (1 ml) daily for 7 successive days. Immediately after the fourth probiotic and medium dose, animals of both groups of A_a and B_a were induced with a single oral dose of AFB₁ in amount of 1.5 mg/kg body weight. Animals of chronic aflatoxicosis study were divided into three subgroups of A_c, B_c, and untreated control group as well. Group A_c was given LcS (10⁸ CFU) by oral gavage daily for 20 successive days, and group B_c received normal saline (1 ml) again daily for 20 successive days. Immediately after the fourth probiotic and medium dose and from the 4th day, rats of both groups of A_c, and B_c started to receive multiple oral dose of AFB₁ in amount of 25 µg/kg body weight daily for 5 days per week over the next 2 weeks.

Based on the analysis of rats' body weight in acute aflatoxicosis, a significant difference was found between control group with the other two groups dosed with AFB₁ (groups A_a and B_a) in days 6 and 7 ($p < 0.05$). However there was no significant difference between groups A_a and B_a, but the mean of rat's body weight was higher in the group A_a. On the other hand there was a significant difference between control group and groups A_a and B_a in terms of blood liver and kidney biomarkers in acute aflatoxicosis ($p < 0.05$). However there was no significant difference between groups

A_a and B_a, the mean values of these biomarkers (ALT, AST, CREA and UREA) were greater in the group B_a in comparison to group A_a. To investigate the effect of LcS on AFB₁ absorption, blood serum level of AFB₁ was measured in all groups and then compared together. As expected aflatoxin B₁ was detected from all of the serum samples expect for untreated control blood serum samples. The mean of AFB₁ blood serum level in the group B_a was higher than group A_a. In the chronic aflatoxicosis study different results were obtained. With regard to rats' body weight; there was a significant difference between group B_c and the other two groups (untreated control and group A_c). This significant difference was found from day 9 to the end of the chronic aflatoxicosis study. Analysis of blood liver enzymes in chronic aflatoxicosis study revealed that there was a significant difference between untreated control group with groups A_c and B_c. A significant difference was also found between group A_c and group B_c ($p < 0.05$). With regards to the level of creatinin and uric acid, similarly to acute aflatoxicosis study, analysis indicated that there was a significant difference between untreated control animals and animals of groups groups A_c and B_c ($p < 0.05$). However no significant difference was found between groups A_c and B_c. AFB₁ was detected from rats serum sampels of groups A_c and B_c, but compared to the acute aflatoxicosis study, there was a significant difference between groups A_c and B_c ($p < 0.05$).

According to the results of this study it can be concluded that probiotic LcS supplementation could improve the adverse effect of AFB₁ induction more effective and significantly in chronic aflatoxicosis study compared to the acute aflatoxicosis study. Therefore longer duration of probiotic LcS supplementation with more

number of animals is suggested for future studies to confirm the ability of probiotic Lcs to reduce the bioavalibility of AFB₁ *in vivo*.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Master Sains

**KESAN PROBIOTIK *LACTOBACILLUS CASEI* STRAIN SHIROTA
TERHADAP TAHAP AFLATOKSIN B₁ DALAM TIKUS YANG DIARUH
DENGAN AFLATOKSIN**

Oleh

ELHAM NIKBAKHT NASRABADI

Februari 2013

Pengerusi: Rosita Binti Jamaluddin, PhD

Fakulti: Perubatan dan Sains Kesihatan

Aflatoksin B₁ (AFB₁) dianggap sebagai bahan pencemar makanan yang paling toksik dengan kesan berbahaya kepada kesihatan manusia dan haiwan yang dihasilkan oleh spesies kulat *Aspergillus* (A.) iaitu *A. flavus* dan *A. parasiticus*. Ia dikelaskan sebagai karsinogen oleh satu kumpulan Agensi Antarabangsa untuk Penyelidikan Kanser yang dikaitkan dengan etiologi kanser hati. Intervensi dan pendekatan pencegahan dengan menumpukan lebih tumpuan kepada langkah-langkah pra dan pasca penuaian bagi mengurangkan tahap AFB₁ dalam tanaman atau pada peringkat individu untuk memodulasi integrasi biologi dan penyingkiran AFB₁ atau mengurangkan kebolehsyerapan biologi tanaman tersebut. Mikro organisma, terutamanya bakteria, telah dikaji potensi mereka untuk mengurangkan kebolehsyerapan biologi aflatoksin serta bahan cemar makanan yang lain. Antara mereka, *lactic acid bacteria* dikenalpasti mempunyai keupayaan untuk mengurangkan kebolehsyerapan biologi aflatoksin *in vitro*.

Penyelidikan ini bertujuan untuk menyiasat kesan bakteria probiotik *Lactobacillus casei* strain Shirota (LcS) terhadap tahap AFB₁ dalam dalam tikus yang diaruh oleh aflatoksin melalui ujian berat, hati dan fungsi buah pinggang, dan juga AFB₁ dalam serum berdasarkan pada dua kajian yang berasingan iaitu akut dan kronik aflatoksin. Akhirnya perbandingan telah dilakukan untuk melihat kesan daripada suplemen probiotik dalam tempoh yang berbeza antara kajian akut dan kronik AFB₁. Untuk mencapai tujuan ini, satu kajian eksperimen telah dijalankan, dan sejumlah 48 ekor tikus telah dibahagikan kepada dua kumpulan (n=24) untuk menjalankan dua kajian iaitu akut dan kronik aflatoksin. Tikus-tikus dalam kajian akut aflatoksin telah dibahagikan kepada tiga kumpulan kecil iaitu A_a, B_a, dan kawalan yang tidak dirawat (n=6). Kumpulan A_a (n=9) menerima probiotik LcS (10⁸ CFU/ml) melalui mulut setiap hari selama 7 hari berturut-turut, dan kumpulan B_a (n=9) menerima kandungan air masin yang sederhana (1 ml) setiap hari selama 7 hari berturut-turut. Sejurus selepas dos yang keempat probiotik dan air masin yang sederhana, tikus di kedua-dua kumpulan A_a dan B_a telah diberikan dengan satu dos AFB₁ sejumlah 1.5 mg/kg berat badan melalui mulut. Tikus-tikus dalam kajian kronik aflatoksin juga telah dibahagikan kepada tiga kumpulan kecil A_c, B_c, dan kumpulan kawalan yang tidak dirawat. Kumpulan A_c telah diberikan probiotik LcS (10⁸ CFU/ml) melalui mulut setiap hari selama 20 hari berturut-turut, dan kumpulan B_c menerima kandungan air masin yang sederhana (1 ml) sekali lagi setiap hari selama 20 hari berturut-turut. Sejurus selepas dos yang keempat probiotik dan kandungan air masin yang sederhana serta dari hari ke-4, tikus dikedua-dua kumpulan A_c, dan B_c telah mula menerima pelbagai dos daripada AFB₁ pada setiap hari sejumlah 25 µg/kg berat badan untuk 5 hari seminggu selama lebih 2 minggu melalui mulut.

Berdasarkan kepada analisis berat badan tikus dalam kumpulan aflatoksin akut, perbezaan yang signifikan didapati di antara kumpulan kawalan dengan dua kumpulan yang lain yang telah diberikan dengan dos AFB₁ (kumpulan A_a dan B_a) pada hari ke-6 dan ke-7 ($p < 0.05$). Walau bagaimanapun, terdapat tiada sebarang perbezaan yang signifikan antara kumpulan yang A_a dan B_a tetapi purata berat badan tikus adalah tinggi dalam kumpulan A_a. Sebaliknya terdapat perbezaan yang signifikan antara kumpulan kawalan dan kumpulan A_a dan B_a dari segi status darah dari hati dan penanda biologi dari buah pinggang dalam kumpulan aflatoksin akut ($p < 0.05$). Walaupun tidak terdapat perbezaan yang signifikan di antara kumpulan A_a dan B_a, purata nilai penanda biologi tersebut (ALT, AST, CREA dan UREA) adalah lebih besar dalam kumpulan B_a berbanding dengan kumpulan A_a. Untuk menyiasat kesan probiotik LcS terhadap penyerapan AFB₁, tahap serum AFB₁ telah diukur dalam semua kumpulan dan kemudian dibandingkan bersama-sama. Seperti yang dijangka, aflatoksin B₁ dikesan daripada semua sampel serum darah untuk kawalan. Purata AFB₁ pada tahap serum darah dalam kumpulan B_a adalah lebih tinggi daripada kumpulan A_a. Dalam kumpulan kronik aflatoksin keputusan yang berbeza telah diperolehi. Dengan mengambil kira berat badan tikus, terdapat perbezaan yang signifikan antara kumpulan B_c dan dua kumpulan lain (kawalan yang tidak dirawat dan kumpulan A_c). Perbezaan yang signifikan ini didapati didapati dari hari ke-9 hingga hari terakhir kajian aflatoksin kronik. Analisis enzim hati dalam darah dalam kajian aflatoksin kronik mendedahkan bahawa terdapat perbezaan yang signifikan antara kumpulan kawalan yang tidak dirawat dengan kumpulan A_c dan B_c. Perbezaan yang signifikan juga didapati antara kumpulan A_c dan kumpulan B_c ($p < 0.05$). Merujuk kepada tahap kreatinin dan asid urik, begitu juga kajian aflatoksin akut, analisis menunjukkan bahawa terdapat perbezaan yang signifikan antara tikus-tikus

dalam kumpulan kawalan yang tidak dirawat dan tikus-tikus dalam kumpulan A_c dan B_c ($p < 0.05$). Walau bagaimanapun, tiada perbezaan yang signifikan didapati antara kumpulan A_c dan B_c. AFB₁ telah dikesan dari sampel serum tikus dari kumpulan A_c dan B_c, tetapi berbanding dengan kajian aflatoxin akut, terdapat perbezaan yang signifikan antara kumpulan A_c dan B_c ($p < 0.05$).

Menurut hasil kajian ini dapat disimpulkan bahawa suplemen probiotik LcS boleh mengurangkan kesan buruk akibat aruhan AFB₁ lebih berkesan dalam kumpulan kajian aflatoxin kronik berbanding kajian aflatoxin akut. Oleh itu, tempoh yang lebih lama untuk pemberian suplemen probiotik LcS dengan bilangan haiwan yang lebih banyak dicadangkan untuk kajian masa depan bagi mengesahkan keupayaan LcS untuk mengurangkan kebolehserapan biologi daripada AFB₁ secara *in vivo*.

ACKNOWLEDGEMENTS

I would like to express my gratitude to all those who supported me and helped me to complete my thesis. My sincere thanks to Dr. Rosita Jamaluddin, her stimulating advises and encouragement supervised me through the research and writing my thesis. I would like to acknowledge the guidance of Assoc. Prof. Dr. Mohd Sokhini Bin Abd Mutalib, my co-supervisor, who helped me and advised me to complete this thesis.

I also thank the Nutrition lab and animal house staff for all their helps and assistance. I acknowledge the Faculty of Medicine and Health Sciences of Universiti Putra Malaysia members and staff and the head of the department of Nutrition and Dietetics for their allowance and assistance to run this experiment.

My deepest gratitude goes to my beloved family, without their endless support I would not have completed this thesis. I would like to thank all my friends who helped me during the research; I sincerely wish all the best for their future endeavors.

I certify that a Thesis Examination Committee has met on 4 February 2013 to conduct the final examination of Elham Nikbakht Nasrabadi on her thesis entitled “Effect of Probiotic *Lactobacillus casei* Shirota Strain on Aflatoxin B₁ Level in Aflatoxin-induced Rats” in accordance with the Universities and University College Act 1971 and the Constitution of the Universiti Putra Malaysia [P.U.(A) 106] 15 March 1998. The committee recommends that the student be awarded the Master of Science.

Members of the Thesis Examination Committee were as follows:

Norhaizan binti Mohd Esa, PhD
Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Amin bin Ismail, PhD
Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Internal Examiner)

Loh Su Peng, PhD
Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Internal Examiner)

Norrakiah binti Abdullah Sani, PhD
Senior Lecturer
Faculty of Science and Technology
Universiti Kebangsaan Malaysia
(External Examiner)



SEOW HENG FONG, PhD
Professor and Deputy Dean
School of Graduate Studies
Universiti Putra Malaysia

Date: 21 March 2013

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfillment of requirement for degree of Master of Science. The members of Supervisory Committee were as follows:

Rosita Binti Jamaluddin, PhD

Senior Lecturer
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Chairman)

Mohd Sokhini Bin Abd Mutalib, PhD

Associate Professor
Faculty of Medicine and Health Sciences
Universiti Putra Malaysia
(Member)


BUJANG BIN KIM HUAT, PhD

Professor and Dean
School of Graduate Studies
Universiti Putra Malaysia

Date:

DECLARATION

I declare that the thesis is my original work except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously, and is not concurrently, submitted for any other degree at Universiti Putra Malaysia or at any other institution.



ELHAM NIKBAKHT NASRABADI

Date: 4 February 2013

TABLE OF CONTENTS

	Page
DEDICATIONS	ii
ABSTRACT	iii
ABSTRAK	vii
ACKNOWLEDGEMENTS	xi
APPROVAL	xii
DECLARATION	xiv
LIST OF TABLES	xviii
LIST OF FIGURES	xix
LIST OF ABBREVIATIONS	xx
CHAPTER	
1 INTRODUCTION	1
1.1 Background	1
1.2 Statement of problem	4
1.3 Significance of study	6
1.4 Objective of study	8
1.4.1 General objective	8
1.4.2 Specific objectives	8
2 LITERATURE REVIEW	9
2.1 Aflatoxin	9
2.1.1 History of aflatoxin	10
2.1.2 Chemistry of major aflatoxins	11
2.1.3 Absorption of aflatoxin B ₁	12
2.1.4 Metabolism of aflatoxin B ₁	13
2.1.5 Excretion of aflatoxin B ₁	18
2.2 Toxicity and carcinogenicity of aflatoxins <i>in vivo</i> system	21
2.2.1 Aflatoxin exposure in human	21
2.2.2 Acute toxicity of aflatoxins in animals	22
2.2.3 Chronic exposure to aflatoxin B ₁ in animals	23
2.3 Probiotic Microorganisms	25
2.3.1 Role of probiotic in health and diseases	27

2.3.2	Antimutagenic and anticarcinogenic effects of probiotics and LAB	32
2.3.3	Aflatoxin binding by probiotics and LAB	34
2.4	<i>Lactobacillus casei</i> Shirota	39
2.4.1	Effect of <i>Lactobacillus casei</i> strain Shirota on cancer	40
2.4.2	Preventive effect of <i>Lactobacillus casei</i> Shirota on life style diseases	42
2.4.3	Other clinical application of <i>Lactobacillus casei</i> Shirota	44
3	METHODOLOGY	47
3.1	Materials and instruments	47
3.2	Probiotic Culturing	47
3.3	Animals	49
3.4	Experimental design	50
3.4.1	Animal study in acute aflatoxicosis	50
3.4.2	Animal study in chronic aflatoxicosis	52
3.5	Blood withdrawal	54
3.6	Determination of liver and kidney enzymes	54
3.6.1	Alanine transaminase analysis	55
3.6.2	Aspartate transaminase analysis	55
3.6.3	Creatinine analysis	56
3.6.4	Urea analysis	56
3.7	Determination of aflatoxin B ₁ blood serum level	56
3.7.1	Extraction and purification of aflatoxin B ₁	57
3.7.2	Enzyme immunoassay for the quantitative analysis of aflatoxin B ₁	58
3.8	Statistical analysis	60
4	RESULTS AND DISCUSSION	62
4.1	Effect of probiotic <i>Lactobacillus casei</i> Shirota strain on the aflatoxin B ₁ level in acute aflatoxicosis rats	62
4.1.1	Effect of <i>Lactobacillus casei</i> Shirota strain on the rats body weight in acute aflatoxicosis	62

4.1.2 Effect of <i>Lactobacillus casei</i> Shirota strain on hepatotoxic effect of AFB ₁ induction through liver function test in acute aflatoxicosis rats	66
4.1.3 Effect of <i>Lactobacillus casei</i> Shirota strain on the kidney function test in acute aflatoxicosis rats	69
4.1.4 The effect of <i>Lactobacillus casei</i> Shirota strain on the absorption of AFB ₁ in acute aflatoxicosis rats	71
4.2 Effect of probiotic <i>Lactobacillus casei</i> Shirota strain on the aflatoxin B ₁ level in chronic aflatoxicosis rats	72
4.2.1 Effect of <i>Lactobacillus casei</i> Shirota strain on the rats body weight in chronic aflatoxicosis	73
4.2.2 Effect of <i>Lactobacillus casei</i> Shirota strain on hepatotoxic effect of AFB ₁ induction through liver function test in chronic aflatoxicosis rats	77
4.2.4 The Effect of <i>Lactobacillus casei</i> Shirota strain on the absorption of AFB ₁ in chronic aflatoxicosis rats	81
4.3 The effect of probiotic <i>Lactobacillus casei</i> Shirota strain supplementation in different duration between acute and chronic aflatoxicosis rats	84
5 SUMMARY, CONCLUSION AND RECOMMENDATIONS FOR FUTURE RESEARCH	90
5.1 Summary and conclusion	90
5.2 Recommendation for future researches	92
REFERENCES	94
APPENDICES	107
BIODATA OF STUDENT	110
LIST OF PUBLICATIONS, PRESENTATIONS AND AWARDS	111

LIST OF TABLES

Table	Page
2.1 Summary of some probiotic health effects	29
4.1 Liver enzymes analysis of acute aflatoxicosis rats	67
4.2 Kidney biomarkers analysis of acute aflatoxicosis rats	69
4.3 Blood liver enzymes analysis of rats in chronic aflatoxicosis	77
4.4 kidney biomarker analysis of rats' blood samples in chronic aflatoxicosis	80
4.5 Liver enzymes comparison between acute and chronic aflatoxicosis studies	85
4.6 Kidney biomarkers comparison between acute and chronic aflatoxicosis	86
4.7 AFB1 serum level comparison between acute and chronic aflatoxicosis	87

LIST OF FIGURES

Figure	Page
2.1 Photo of invaded corn by aflatoxin	9
2.2 Chemical structures of major dietary aflatoxins	11
2.3 Major metabolic pathways of AFB ₁	15
3.1 Experimental design of acute aflatoxicosis study	51
3.2 Experimental design of chronic aflatoxicosis study	53
3.3 Extraction of AFB ₁ from collected serum samples	58
4.1 Comparison of rats' body weight gain between the three groups of A _a , B _a , and C _a , during 7 days in acute aflatoxicosis	64
4.2 AFB ₁ serum level, quantified by immunoassay (ELISA), comparisons between three groups in acute aflatoxicosis	71
4.3 Comparison of rats' body weight gain between the three groups of A _c , B _c , and C _c during 20 days in chronic aflatoxicosis	74
4.4 AFB ₁ blood serum level, quantified by immunoassay (ELISA), comparisons between the three groups in chronic aflatoxicosis	82

LIST OF ABBREVIATIONS

ACUC	Animal Care and Use Committee
AFB ₁	Aflatoxin B ₁
AFB ₁ GSH	Aflatoxin B ₁ Glutathione conjugate
AFB ₂	Aflatoxin B ₂
AFG ₁	Aflatoxin G ₁
AFG ₂	Aflatoxin G ₂
AFL	Aflatoxicol
AFM ₁	Aflatoxin M ₁
AFM ₂	Aflatoxin M ₂
AFP ₁	Aflatoxin P ₁
AFQ ₁	Aflatoxin Q ₁
ALA	Alpha linolenic acid
ALP	Alkaline phosphatase
ALT	Alanine aminotransferase
ANOVA	Analysis of variance
AST	Aspartate aminotransferase
ATP	Adenosine triphosphate
Bhd	Berhad
CFU	Colony forming unit
CYP	Cytochrome P450
EDTA	Ethylenediaminetetraacetic acid
GG	<i>Lactobacillus rhamnosus</i> strain GG
HCA	Heterocyclic Amines
GGT	Gamma glutamyl transpeptidase

HPLC	High performance liquid chromatography
IAC	Immunoaffinity column
IARC	International Agency for Research on Cancer
LAB	Lactic acid bacteria
LC705	<i>Lactobacillus rhamnosus</i> strain LC705
LD50	Lethal dose, 50%
PJS	<i>Propionibacterium freudenreichii</i> ssp. <i>Shermanii</i> JS
USA	United State of America
WHO	World Health Organization
α	Alpha
β	Beta
γ	Gama
ω	Omega
Δ	Delta
$^{\circ}\text{C}$	Degree centigrade
<	Lower than
>	More than
\pm	Plus and mines
%	Percentage
μ	Micro
μl	Microliter
L	Liter
dl	Deciliter
d	Day
cc (ml)	Milliliter
cm	Centimeter
M	Molar

m	Meter
mm	Millimeter
mg	Milligram
mmol	Millimol
nm	Nanometer
kg	Kilogram
g	Gram
w (Wt)	Weight
v	Volume
U (IU)	International unit
Min	Minute
<i>p</i>	<i>p</i> value
mAU	Peak area
C ₁₈	Carbon 18
H ₂ O	Water
NH ₄ SCN	Ammonium thiocyanate
O ₂	Oxygen
RCOOH	Carboxylic Acids

CHAPTER 1

INTRODUCTION

1.1 Background

Food is the fuel of life, and everyone is concerned about the quality and safety of food. Harmful components in plant derived foods can be produced by the plant itself, or contaminants derived from either man-made sources or microorganisms. Among these microorganisms, toxin producing fungi are ubiquitous in the environment and can invade the crops and produce toxic secondary metabolites known as mycotoxins. Mycotoxins can appear in the food chain as a result of fungal infection of crops, which are either eaten by humans or through those used as livestock feed. Low-level chronic exposure to mycotoxins can induce chronic toxic effects in human, such as carcinogenic and estrogenic effect (Bennett & Klich, 2003), mutagenicity (Lehmann et al., 2006), teratogenicity (Creppy, 2002), and high-level exposure can cause acute disease (Robbins et al., 2000), which may result in death.

Aflatoxins are the most important mycotoxins. They can be produced by four toxic species of *Aspergillus* (*A.*), which are *A. flavus*, *A. flavus ssp. parasiticus*, *A. nomius* and *A. pseudotamarii* (Pitt, 2000) as secondary metabolites. Aflatoxins commonly contaminate maize and groundnuts, and are categorized as group one human carcinogens by the International Agency for Research on Cancer which is linked to the etiology of liver cancer (IARC, 2002).

At least 13 different types of aflatoxin are produced in nature. Aflatoxin B₁ (AFB₁) is considered as the most toxic and is produced by both *A. flavus* and *A. parasiticus*. Aflatoxins G₁ and G₂ are produced by *A. parasiticus*. Aflatoxins M₁ and M₂ were originally discovered in the milk of cows, which were fed on moldy grain. These compounds are products of a conversion process in the animal's liver. However, aflatoxin M₁ is present in the fermentation broth of *A. parasiticus* (Boutrif, 1998).

Microorganisms, especially bacteria, have been studied for their potential to either degrade mycotoxins or reduce their bioavailability. Among these bacteria and probiotics, *lactic acid bacteria* (LAB) have been known to have the ability to reduce the bioavailability of aflatoxins *in vitro* (Gratz et al., 2005). Furthermore, probiotic bacteria exert a number of other beneficial health effects, which make them even more suitable as additives for both food and feed.

Probiotics are dietary supplements of live microorganisms shown to be healthy for the host organism. According to the currently adopted definition by FAO/WHO (2001), probiotics are: "Live microorganisms which when administered in adequate amounts confer a health benefit on the host". LAB and *Bifidobacteria* are the most common types of microbe used as probiotics; however, certain yeasts and bacilli might also be helpful (Srividya & Vishnuvarthan, 2011).

The term "probiotics" indeed was first introduced by Kollath in 1953 (Hamilton-Milleret, 2003). At that time, probiotics were defined as microbially derived factors

that can stimulate the growth of other microorganisms. Fuller (1989) suggested a definition of probiotics that has been widely used: "A live microbial feed supplement which beneficially affects the host animal by improving its intestinal microbial balance". In the following decades, intestinal LAB species that were considered to have beneficial health properties were introduced as probiotics, including *Lactobacillus (L.) rhamnosus*, *L. casei*, and *L. johnsonii* (Tannock, 2003).

When discussing probiotic bacteria, the term LAB is often used. LAB constitute a heterogeneous group of gram-positive, low-GC (G and C refer to the guanine and cytosine content in their genomes), acid-tolerant, generally non-sporing, non-respiring cocci or rods, producing lactic acid as the major end product of carbohydrate fermentation and include strains from the genera *Aerococcus*, *Alliococcus*, *Carnobacterium*, *Enterococcus*, *Lactobacillus*, *Lactococcus*, *Lactoshaera*, *Leuconostoc*, *Oenococcus*, *Pediococcus*, *Streptococcus*, *Tetragenococcus*, *Vagococcus* and *Weissella* (Axelsson, 2004). As probiotics, only strains from the genus *Lactobacillus* (e.g., *L. acidophilus*, *L. bulgaricus*, *L. casei*, *L. plantarum*, *L. reuteri*, and *L. rhamnosus*) are used.

Probiotics have been successfully incorporated in a number of foods including the traditional vehicle of fermented milks and yogurts, and increasingly in other fermented and non-fermented foods beyond the dairy sector. Dairy products include fermented milk, yogurt, frozen yogurt, kefir, matured cheese, fresh cheese, ice cream, dairy desert, fermented soymilk, fermented cereal products, dry products, such as infant formula and nutritional powders, some juices, fermented meats, and

confectionary products. Furthermore, probiotics can be added to fresh service products, such as sandwiches, sushi, and smoothies, which can be refrigerated.

1.2 Statement of problem

Toxins are regularly ingested. A number of toxins come from foods eaten every day. Mycotoxins represent one of the important classes of naturally occurring toxicants in food, which poses a considerable health risk (Shetty & Jespersen, 2006). Mycotoxins heavily resist decomposition or breaking down in digestion, and, therefore, will remain in the food chain. They cannot even be destroyed by temperature treatments such as cooking and freezing (Bennett & Klich, 2003). Low levels of exposure to mycotoxins occur in some parts of the world where food is available in higher quality and variety; whereas high level exposure exists in areas where populations depend on a single staple food commodity (Wild & Gong, 2010).

As mentioned earlier, the most important mycotoxins are aflatoxins, and since no animal species has resistance to the acute toxic effects of aflatoxins, it is reasonable to assume that humans may be correspondingly affected. The chronic exposure to aflatoxins of farm and laboratory animals compromises immunity and interferes with protein metabolism and multiple micronutrients that are crucial to health. The prevalence and level of human exposure to aflatoxins on a global scale have been reviewed, and the result indicates that approximately 4.5 billion persons living in

developing countries are chronically exposed to largely uncontrolled amounts of the toxin (Williams et al., 2004).

An outbreak of food poisoning resulting in 13 deaths in children occurred in Malaysia during the Chinese Festival of the Nine-Emperor Gods in 1988. The offending food was a Chinese noodle called 'Loh See Fun' (LSF). The source was traced to a factory where a banned food preservative was added to make the LSF. The food poisoning was attributable to aflatoxins and boric acid (Chao et al., 1991). Moreover several studies reported aflatoxin contamination in foodstuffs in Malaysia (Arzandeh et al., 2010; Leong et al., 2011).

Furhteremore there is no non-drug supplement to reduce the level of aflatoxin in human body. The use of non-nutritional aflatoxin adsorbents such as clays or activated carbons can cause toxicity and pose harmful effect (Kabak & Ozbey, 2012).

On the other hand, there are several hypotheses suggesting the mechanisms of probiotics and toxin. Fermentation of food has been used as a method of preservation for centuries, and LAB are reported to reduce mold growth and aflatoxin production (Mokoena et al., 2006). Several bacterial strains, of food or human origin, have been tested for their ability to bind aflatoxins and other mycotoxins to the bacterial cell wall (El-Nezami et al., 2002a; El-Nezami et al., 2002b; Styriak & Conkova, 2002). Under *in vivo* conditions, it is expected that

probiotic bacteria bind AFB₁ as soon as they interact with each other inside the intestinal tract, and, also, numerous studies reveal the benefits of probiotics to human health. Thus, the goal of this study is to identify the potential of a probiotic, specifically, *Lactobacillus casei* Shirota strain (LcS), on toxin reduction in acute and chronic aflatoxicosis rats.

The following are the research questions that are addressed in this study:

1. Is there any difference in the body weight of rats that are dosed with aflatoxin and those given probiotic LcS plus aflatoxin in acute and chronic aflatoxicosis?
2. In aflatoxin-induced rats, does probiotic LcS have any impact on hepatotoxic effect of AFB₁ and also the elevation of kidney biomarkers, in acute and chronic aflatoxicosis?
3. What is the efficacy of probiotic LcS in reducing the absorption of aflatoxin B₁ in acute and chronic aflatoxicosis rats?
4. Is there any difference in probiotic LcS supplementation efficacy in terms of duration between acute and chronic aflatoxicosis rats?

1.3 Significance of study

Biological decontamination of mycotoxins using microorganisms is one of the renowned strategies for the management of mycotoxins in foods and feeds. Among

the different potential decontaminating microorganisms, LAB represents unique groups, which are widely used in food fermentation and preservation.

Aflatoxin B₁ as mentioned previously is an important food contaminant with a detrimental effect on human and animal health. Intervention approaches concentrate on pre- and post-harvest measures to reduce AFB₁ levels in crops or on the individual level to regulate bioactivation and excretion of AFB₁ or reduce its bioavailability (Khlanguiset & Wu, 2010). Probiotic bacteria have been known to have the capacity to reduce the bioavailability of AFB₁ as well as other food contaminants (Styriak & Conkova, 2002).

This study compared the effect of probiotic LcS in two different durations of toxin induction namely acute and chronic aflatoxicosis. No study has been done before to compare the effect of probiotic LcS in acute and chronic aflatoxicosis. Furthermore, probiotics and specially LcS propose a wide range of potentially beneficial medicinal uses. Therefore, it is hoped that this research can be useful in contributing to the knowledge of reducing the level of toxins *in vivo* by applying probiotics. Hence, it may provide knowledge for nutritionist and health practitioners concerning the importance of probiotics LcS for human health. This exclusive bacterium, which is also called Shirota strain has been tested for its beneficial role in the digestive tract, such as improving bowel movement, maintaining balance of intestinal flora, Boosting the immune system, and finally reducing toxins in the intestines (Spanhaak et al., 1998).

1.4 Objective of study

1.4.1 General objective

To investigate the effect of probiotic *Lactobacillus casei* Shirota strain on aflatoxin B₁ level in acute and chronic aflatoxicosis rats.

1.4.2 Specific objectives

1. To determine the effect of LcS on the rats body weight that are dosed with AFB₁ in acute and chronic aflatoxin exposure.
2. To determine the effect of LcS on hepatotoxic effect of AFB₁ induction through liver function test and also kidney biomarkers in acute and chronic aflatoxicosis rats.
3. To determine the effect of LcS on AFB₁ absorption through AFB₁ blood serum level of acute and chronic aflatoxicosis rats.
4. To compare the effect of probiotic LcS supplementation in the same daily dosage, but different duration between acute and chronic aflatoxicosis rats.

REFERENCES

- Abdel-Wahhab, M.A., & Aly, S.E. (2003). Antioxidants and radical scavenging properties of vegetable extracts in rats fed aflatoxin-contaminated diet. *Journal of Agricultural and Food Chemistry*, 51, 2409-2414.
- Abdel-Wahhab, M.A., & Kholif, A.M. (2008). Mycotoxin in animal feeds and prevention strategies: a review. *Asian Journal of Animal Sciences*, 2 (1), 7-25.
- Abdel-Wahhab, M.A., Abdel-Azm, S.H., & El-Nekeety, A.A. (2008). Inula crithmoides extract protects against ochratoxin A-induced oxidative stress, clastogenic and mutagenic alterations in male rats. *Toxicol*, 52, 566-573.
- Abdel-Wahhab, M.A., Ahmed, H.H., & Hagazi, M.M. (2006). Prevention of aflatoxin B₁-initiated hepatotoxicity in rat by marine algae extracts. *Journal of Applied Toxicology*, 26, 229-238.
- Abdel-Wahhab, M.A., Omara, E.A., Abdel-Galil, M.M., Hassan, N.S., Nada, S.A., Saeed, A., & et al. (2007). Zizyphus Spina-Christi extract protects against aflatoxin B₁-inhibited Hepatic Carcinogenicity. *African Journal of Traditional, Complementary and Alternative Medicines*, 4 (3), 248-256.
- Afsah-Hejri, L. Jinap, S. Arzandeh, S. & Mirhosseini, H. (2011). Optimization of HPLC conditions for quantitative analysis of aflatoxins in contaminated peanut. *Food Control*, 22, 381-388.
- Arzandeh, S., Selamat, J., & Lioe, H. (2010). Aflatoxin in raw peanut kernel marketed in Malaysia. *Journal of Food and Drug Analysis*, 18, 44-50.
- Aso, Y., Akaza, H., Kotake, T., Tsukamoto, T., Imai, K., & Naito, S. (1995). Preventive effect of a Lactobacillus casei preparation on the recurrence of superficial bladder cancer in a double-blind trial. The BLP Study Group. *European Urology*, 27(2), 104-109.
- Axelsson, L. (2004). Lactic acid bacteria: classification and physiology. In S. Salminen, A. von Wright, & A. Ouwehand (Eds.), *Lactic Acid Bacteria, Microbiological and Functional Aspects, 3rd Edition* (pp. 1-66). New York: Marcel Decker.
- Azziz-Baumgartner, E., Lindblade, K., Giesecker, K., Rogers, H.S., Kieszak, & Henry Njapau, S., et al. (2005). Case-Control Study of an Acute Aflatoxicosis Outbreak, Kenya, 2004. *Environ Health Perspect*, 113(12), 1779-1783.
- Bailey, E.A., Iyer, R.S., Stone, M.P., Harris, T.M., & Essigmann, J.M. (1996). Mutational properties of the primary aflatoxin B₁-DNA adduct. *Proceeding of the National Academy of Sciences of the United States of America*, 93, 1535-1539.
- Barber, M.D., McMillan, D.C., Wallace, A.M., Ross, J.A., Preston, & T., Fearon, K.C. (2004). The response of leptin, interleukin-6 and fat oxidation to feeding

- in weight-losing patients with pancreatic cancer. *British Journal of Cancer*, 90, 1129-1132.
- Bennett, J.W., & Klich, M. (2003). Mycotoxins. *Clinical Microbiology Reviews*, 16(3), 497-516.
- Bolognani, F., Rumney, C.J., & Rowland, I.R. (1997). Influence of carcinogen binding by lactic acid producing bacteria on tissue distribution and *in vivo* mutagenicity of dietary carcinogens. *Food Chemistry and Toxicology*, 35, 535-545.
- Boutrif, E. (1998). Prevention of aflatoxin in pistachios. *Food, Nutrition and Agriculture*, 21, 32-38.
- Boyle, R.J., Robins-Browne, R.M., & Tang, M.L. (2006). Probiotic use in clinical practice: what are the risks? *American Journal of Clinical Nutrition*, 83, 1256-1264.
- Busby, W.F., & Wogan, G.N. (1984). Aflatoxins. In C.E. Searle (Eds.), *Chemical Carcinogens* (pp. 945-1136). Washington, D.C.: American Chemical Society.
- Camilleri, M. (2006). Probiotics and Irritable Bowel Syndrome: Rationale, Putative Mechanisms, and Evidence of Clinical Efficacy. *Journal of Clinical Gastroenterology*, 40(3), 264-269.
- Cardwell, K.F., & Henry, S.H. (2004). Risk of exposure to and mitigation of effect of aflatoxin on human health: a west african example. *Journal of Toxicology*, 23(2), 217-247.
- Casas, I.A., & Dobrogosz, W.J. (2000). Validation of the probiotic concept: *Lactobacillus reuteri* confers broad-spectrum protection against disease in humans and animals. *Microbial Ecology in Health and Disease*, 12, 247-285.
- Chao, T.C, Maxwell, S.M, Wong, S.Y. (1991). An outbreak of aflatoxicosis and boric acid poisoning in Malaysia: a clinicopathological study. *Journal of Pathology*, 164, 225-233.
- Collado, M.C. (2009). Role of probiotics in health and disease. In Y.K. Lee, & S. Salminen (Eds.), *Handbook of probiotics and prebiotics* (pp. 257-376). New Jersey, New York: John Wiley & Sons.
- Collado, M.C., Meriluoto, J., & Salminen, S. (2007). *In vitro* analysis of probiotic strain combinations to inhibit pathogen adhesion to human intestinal mucus. *Food Research International*, 40(5), 629-636.
- Commane, D., Hughes, R., Shortt, C., & Rowland, I. (2005). The potential mechanisms involved in the anticarcinogenic action of probiotics. *Mutation Research*, 591, 276-289.

- Council for Agriculture, Science and Technology (CAST) (2003). Mycotoxins: Risks in Plant, Animal and Human Systems, *In: Task force report No. 139*. Ames, Iowa, USA.
- Creppy, E.E. (2002). Update of survey, regulation and toxic effects of mycotoxins in Europe. *Toxicology Letters*, 127(1-3), 19-28.
- Cullen, J.M., & Newberne P.M. (1994). Acute Hepatotoxicity of Aflatoxins. In D.L. Eaton & J. Groopman (Eds.), *The Toxicology of Aflatoxins: Human Health, Veterinary and Agricultural Significance* (pp. 326). New York: Academic Press.
- Cummings, J.H. (1997). Diet and Large Bowel Cancer. *The Large Intestine in Nutrition and Disease* (pp. 103-110). Bruxelles: Institute Danone.
- Degen, G.H., & Neumann, H.G. (1978). Major Metabolite of Aflatoxin B₁ in Rat Is a Glutathione Conjugate. *Chemico-Biological Interactions*, 22, 239-255.
- Deshpande, S.S. (2002). *Handbook of food toxicology* (p. 391). New York & Basel: Marcel Dekker.
- Donohue, D.C. (2004). Safety of Novel Probiotic Bacteria. In S. Salminen, A. von Wright, & A. Ouwehand (Eds.), *Lactic Acid Bacteria, Microbiological and Functional Aspects* (pp. 531-546). New York: Marcel Decker.
- Dragan, Y.P., & Pitiot, H.C. (1994). Aflatoxin carcinogenesis in the context of the multistage nature of cancer. In D.L. Eaton & J. Groopman (Eds.), *The Toxicology of Aflatoxins: Human Health, Veterinary and Agricultural Significance* (pp. 179-206). New York: Academic Press.
- Eaton, D.L., & Gallagher, E.P. (1994). Mechanisms of aflatoxin carcinogenesis. *Annual Review of Pharmacology and Toxicology*, 34, 135-172.
- Eaton, D.L., Ramsdell, H.S., & Neal, G.E. (1994). Biotransformation of Aflatoxins. In D.L. Eaton & J. Groopman (Eds.), *The Toxicology of Aflatoxins: Human Health, Veterinary and Agricultural Significance* (pp. 45-71). New York: Academic Press.
- El-Nezami, H., Haskard, C., Salminen, E., Mykkanen, A., Ahokas, J., & Salminen, S. (2002a). Lactic acid bacteria and Bifidobacteria can reduce dietary exposure to aflatoxins. *British Journal of Nutrition*, 88, 115-116.
- El-Nezami, H., Kankaanpaa, P., Salminen, S., & Ahokas, J. (1998). Physicochemical alterations enhance the ability of dairy strains of lactic acid bacteria to remove aflatoxin from contaminated media. *Journal of Food Protection*, 61, 466-468.
- El-Nezami, H., Mykkänen, H., Kankaanpää, P., Salminen, S., & Ahokas, J. (2000a). Ability of *Lactobacillus* and *Propionibacterium* strains to remove aflatoxin B₁ from the chicken duodenum. *Journal of Food Protection*, 63, 549-552.

- El-Nezami, H., Mykkänen, H., Kankaanpää, P., Suomalainen, T., Salminen, S., & Ahokas, J. (2000b). Ability of a mixture of *Lactobacillus* and *Propionibacterium* to influence the faecal aflatoxin content in healthy Egyptian volunteers: a pilot clinical study. *Bioscience Microflora*, *19*, 41-45.
- El-Nezami, H.S., Chrevatidis, A., Auriola, S., Salminen, S., & Mykkanen, H., (2002b). Removal of common Fusarium toxins in vitro by strains of Lactobacillus and Propionibacterium. *Food Additives and Contaminants: Part A*, *19*, 680-686.
- Fernandez, A., Belio, R., Ramos, J.J., Sanz, M.C., & Saez, T. (1997). Aflatoxins and their metabolites in the tissues, faeces and urine from lambs feeding on an aflatoxin contaminated diet. *Journal of the Science of Food and Agriculture*, *74*, 161-168.
- Fink-Gremmels, J. (1999). Mycotoxins: Their implications for human and animal health. *Vet Q*, *21*, 115-120.
- Firmin, S., Gandia, P., Morgavi, D.P., Houin, G., Jouany, J.P., Bertin G., & et al. (2010). Modification of aflatoxin B₁ and ochratoxin A toxicokinetics in rats administered a yeast cell wall preparation. *Food Additives and Contaminants*, *27*(8), 1153-1160.
- Food and Agriculture Organization (FAO) & World Health Organization (WHO) (2001). Health and nutritional properties of probiotics in food including powder milk with live lactic acid bacteria. Report of a joint FAO/WHO expert consultation on evaluation of health and nutritional properties of probiotics in food including powder milk with live *lactic acid bacteria*.
- Fuller, R. (1989). Probiotics in man and animals. *The Journal of Applied Bacteriology*, *66* (5), 365-378.
- Gallagher, E.P., Kunze, K.L., Stapleton, P.L., & Eaton, D. L. (1996). The kinetics of aflatoxin B₁ oxidation by human cDNAexpressed and human liver microsomal cytochromes P450 1A2 and 3A4. *Toxicology and Applied Pharmacology*, *141*, 595-606.
- Gong, Y.Y., Cardwell, K., Hounsa, A., Egal, S., Turner, P.C., Hall, A.J., & et al. (2002). Dietary aflatoxin exposure and impaired growth in young children from Benin and Togo: cross sectional study. *British Medical Journal*, *325*, 20-21.
- Gong, Y.Y., Egal, S., Hounsa, A., Turner, P.C., Hall, A. J., Cardwell, K.F., & et al. (2003). Determinants of aflatoxin exposure in young children from Benin and Togo, West Africa: the critical role of weaning. *International Journal of Epidemiology*, *32*, 556-562.
- Gotteland, M., Brunser, O., & Cruchet, S. (2006). Systematic review: are probiotics useful in controlling gastric colonization by *Helicobacter pylori*? *Alimentary Pharmacology and Therapeutics*, *23*(8), 1077-1086.

- Gratz, S. (2007). *Aflatoxin Binding by Probiotics: Experimental Studies on Intestinal Aflatoxin Transport, Metabolism and Toxicity*. Published doctoral dissertation, University of Kuopio, Finland.
- Gratz, S., Mykkänen, H., & El-Nezami, H. (2005). Aflatoxin B₁ binding by a mixture of *Lactobacillus* and *Propionibacterium*: In vitro versus ex vivo. *Journal of Food Protection*, 68(11), 2470-2474.
- Gratz, S., Mykkänen, H., Ouwehand, A.C., Juvonen, R., Salminen, S. & El-Nezami, H. (2004). Intestinal mucus alters the ability of probiotic bacteria to bind aflatoxin B₁ *in vitro*. *Applied and Environmental Microbiology*, 70, 6306-6308.
- Guengerich, F.P. (2001). Minipig cytochrome P450 3A, 2A and 2C enzymes have similar properties to human analogs. *BMC Pharmacology*, 1, 11.
- Guengerich, F.P., Ueng, Y.F., Kim, B.R., Langouet, S., Coles, B., Iyer, R.S., & et al. (1996). Activation of toxic chemicals by cytochrome P450 enzymes: regioand stereoselective oxidation of aflatoxin B₁. *Advances in Experimental Medicine and Biology*, 387, 7-15.
- Hamilton-Miller, J.M.T. (2003). The role of probiotics in the treatment and prevention of *Helicobacter pylori* infection. *International Journal of Antimicrobial Agents*. 22(4), 360-366.
- Haskard, C.A., El-Nezami, H.S., Kankaanpää, P.E., Salminen, S., & Ahokas, J.T. (2001). Surface binding of aflatoxin B₁ by lactic acid bacteria. *Applied and Environmental Microbiology*, 67, 3086-3091.
- Hathout, A.S., Mohamed, S.R., El-Nekeety, A.A., Hassan, N.S., Aly, S.E., & Abdel-Wahhab, M.A. (2011). Ability of *Lactobacillus casei* and *Lactobacillus reuteri* to protect against oxidative stress in rats fed aflatoxins-contaminated diet. *Toxicon*, 58, 179-186.
- Hengstler, J.G., Van der Burg, B., Steinberg, P., & Oesch, F. (1999). Interspecies differences in cancer susceptibility and toxicity. *Drug Metabolism Reviews*, 31, 917-970.
- Herías, M.V., Koninkx, J.F., Vos, J.G., Huis in't Veld, J.H., & van Dijk, J.E. (2005). Probiotic effects of *Lactobacillus casei* on DSS-induced ulcerative colitis in mice. *International Journal of Food Microbiology*, 103(2), 143-155.
- Hernandez-Mendoza, A., González-Córdova, A.F., Vallejo-Cordoba, B., & Garcia, H.S. (2011). Effect of oral supplementation of *Lactobacillus reuteri* in reduction of intestinal absorption of aflatoxin B₁ in rats. *Basic Microbiology*. 51, 263-268.
- Hirayama, K., & Rafter, J. (2000). The role of probiotic bacteria in cancer prevention. *Microbes and Infection*, 2, 681-686.

- Hong-Lim, L., Yan-Li, H., Hui-Huang, C., Wah-Lee, B., Kun-Lee, Y., & Yan-Chua, K. (2008). The effect of heat-killed wild-type *Lactobacillus casei* Shirota on allergic immune responses in an allergy mouse model. *International Archives of Allergy and Immunology*, 148, 297-304.
- Hosoda, M., Hashimoto, H., He, F., Morita, H., & Hosono, A. (1996). Effect of administration of milk fermented with *Lactobacillus acidophilus* LA2 on fecal mutagenicity and microflora in the human intestine. *Journal of Dairy Science*, 79, 745-749.
- Hsieh, D. P.H., & Wong, J.J. (1994). Pharmacokinetics and Excretion of Aflatoxins. In D.L. Eaton & J. Groopman (Eds.), *The Toxicology of Aflatoxins: Human Health, Veterinary and Agricultural Significance* (pp. 73-88). New York: Academic Press.
- Hwang, K.T., Lee, W., Kim, G.Y., Lee, J., & Jun, W. (2005). The Binding of Aflatoxin B₁ Modulates the Adhesion Properties of *Lactobacillus casei* KCTC 3260 to a HT29 Colon Cancer Cell Line. *Food Science Biotechnology*, 14, 866-870.
- International Agency for Research on Cancer (IARC) (2002). monographs on the evaluation of carcinogenic risks to humans: *Some traditional herbal medicines, some mycotoxins, naphthalene and styrene*, 82. <http://monographs.iarc.fr/ENG/Monographs/vol82/mono82.pdf>
- Jakhar, K.K. & Sadana, J.R. (2004). Sequential pathology of experimental aflatoxicosis in quail and the effect of selenium supplementation in modifying the disease process. *Mycopathologia*, 157(1), 99-109.
- Kabak, B., & Ozbey, F. (2012). Aflatoxin M₁ in UHT milk consumed in Turkey and first assessment of its bioaccessibility using an in vitro digestion model. *Food Control*, 28, 338-344.
- Kalliomäki, M., Salminen, S., Arvilommi, H., Kero, P., Koskinen, P., & Isolauri, E. (2001). Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial. *The Lancet*, 357, 1076-1079.
- Kamdem, L.K., Meineke, I., Godtel-Armbrust, U., Brockmoller, J., & Wojnowski, L. (2006). Dominant contribution of P450 3A4 to the hepatic carcinogenic activation of aflatoxin B₁. *Chemical Research in Toxicology*, 19, 577-586.
- Kankaanpää, P., Tuomola, E., El-Nezami, H., Ahokas, J., & Salminen, S.J. (2000). Binding of aflatoxin B₁ alters the adhesion properties of *Lactobacillus rhamnosus* strain GG in a Caco₂ model. *Journal of Food Protection*, 63, 412-414.
- Kew, M.C. (2003). Synergistic interaction between aflatoxin B₁ and hepatitis B virus in hepatocarcinogenesis. *Liver International Journal*, 23, 405-409.

- Khlangwiset, P., & Wu, F. (2010). Costs and efficacy of public health interventions to reduce aflatoxin-induced human disease. *Food Additives and Contaminants: Part A*, 27, 998-1014.
- Kikuchi-Hayakawa, H., Shibahara-Sone, H., Osada, K., Onodera-Masuoka, N., Ishikawa, F., & Watanuki, M. (2000). Lower Plasma Triglyceride Level in Syrian Hamsters Fed on Skim Milk Fermented with *Lactobacillus casei* strain Shirota. *Bioscience, Biotechnology, and Biochemistry*, 64, 466-475.
- Knasmüller, S., Mersch-Sundermann, V., Kevekordes, S., Darroudi, F., Huber, W.W., Hoelzl, C., et al. (2004). Use of humanderived liver cell lines for the detection of environmental and dietary genotoxicants; current state of knowledge. *Toxicology*, 198, 315-328.
- Kumagai, S. (1989). Intestinal absorption and excretion of aflatoxin in rats. *Toxicology and Applied Pharmacology*, 97, 88-97.
- Lahtinen, S.J., Haskard, C.A., Ouwehand, A.C., Salminen, S.J., & Ahokas, J.T. (2004). Binding of aflatoxin B₁ to cell wall components of *Lactobacillus rhamnosus* strain GG. *Food Additives and Contaminants*, 21, 158-164.
- Lankaputhra, W.E., & Shah, N.P. (1998). Antimutagenic properties of probiotic bacteria and of organic acids. *Mutation Research*, 397, 169-182.
- Lee, Y.K. (2009). Probiotic microorganism. In Y.K. Lee & S. Salminen (Eds.), *Handbook of probiotics and prebiotics* (pp. 3-176). New Jersey, New York: John Wiley & Sons.
- Lee, Y.K., El-Nezami, H., Haskard, C.A., Gratz, S., Puong, K.Y., Salminen, S., & et al. (2003). Kinetics of adsorption and desorption of aflatoxin B₁ by viable and nonviable bacteria. *Journal of Food Protection*, 66, 426-430.
- Lehmann, L., Wagner, J. & Metzler, M. (2006). Estrogenic and clastogenic potential of the mycotoxin alternariol in cultured mammalian cells. *Food and Chemical Toxicology*, 44(3), 398-408.
- Leong, Y.H., Rosma, A., Latiff, A.A., & Ahmad, N.I. (2011). Exposure assessment and risk characterization of aflatoxin B₁ in Malaysia. *Mycotoxin Research*, 27, 2017-2014.
- Lesson, S., Diaz, G., & Summers, J. (1995). *Poultry Metabolic Disorders and Mycotoxins. University Books* (pp. 249-298). Montreal, Canada.
- Lichtenstein, A.H., & Goldin, B.R. (2004). *Lactic Acid Bacteria and Intestinal Drug and Cholesterol Metabolism*. In S. Salminen, A. von Wright, & A. Ouwehand (Eds.), *Lactic Acid Bacteria, Microbiological and Functional Aspects* (pp. 507-514). New York: Marcel Decer.

- Logrieco, A., Bottalico, A., Mule, G., Moretti, A., & Perrone, G. (2003). Epidemiology of toxigenic fungi and their associated mycotoxins for some Mediterranean crops. *European Journal of Plant Pathology*, 109, 645-667.
- Lu, H., & Li, Y. (2002). Effects of bicyclol on aflatoxin B₁ metabolism and hepatotoxicity in rats. *Acta Pharmacologica Sinica*, 23, 942-945.
- Massey, T.E., Stewart, R.K., Daniels, J.M., & Liu, L. (1995). Biochemical and Molecular Aspects of Mammalian Susceptibility to Aflatoxin B₁ Carcinogenicity. *Proceedings of the Society for Experimental Biology and Medicine*, 208, 213-227.
- Mata, J.E., Yu, Z., Gray, J.E., Williams, D.E., & Rodriguez-Proteau, R. (2004). Effects of chlorophyllin on transport of dibenzo (a, l) pyrene, 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine, and aflatoxin B₁ across Caco2 cell monolayers. *Toxicology*, 196, 117-125.
- Matsuzaki, T., Saito, M., Usuku, K., Nose, H., Izumo, S., Arimura, K., & et al. (2005). A prospective uncontrolled trial of fermented milk drink containing viable *Lactobacillus casei* strain Shirota in the treatment of HTLV-1 associated myelopathy/tropical spastic paraparesis. *Journal of the Neurological Science*, 237, 75-81.
- Maxuitenko, Y.Y., North, W.G., & Roebuck, B.D. (1997). Urinary taurine as a noninvasive marker of aflatoxin B₁ induced hepatotoxicity: Success and failure. *Toxicology*, 118, 159-169.
- Mayura, K., Abdel-Wahhab, M.A., McKenzie, K.S., Sarr, A.B., Edwards, J.F., Naguib, K., & et al. (1998). Prevention of maternal and developmental toxicity in rats via dietary inclusion of common aflatoxin sorbents: potential for Hidden Risks. *Toxicology Science*, 41, 175-182.
- McLean, M., & Dutton, M.F. (1995). Cellular interactions and metabolism of aflatoxin: an update. *Clinical Pharmacology and Therapeutics*, 65, 163-192.
- Miller, D.M., & Willson, D.M. (1994). Veterinary Diseases Related to Aflatoxins. In: Eaton, L.D., Groopman, & J.D. (Eds.), *The Toxicology of Aflatoxins* (pp. 347-364). San Diego, California State: Academic Press.
- Mokoena, M.P., Chelule, P.K., & Gqaleni, N. (2006). The toxicity and decreased concentration of aflatoxin B in natural lactic acid fermented maize meal. *Journal of Applied Microbiol*, 100(4), 773-777.
- Mykkänen, H., Zhu, H.L., Salminen, E., Juvonen, R.O., Ling, W.H., & Ma, J. (2005). Fecal and urinary excretion of aflatoxin B₁ metabolites (AFQ₁, AFM₁ and AFBN₇guanine) in young Chinese males. *International Journal of Cancer*, 115, 879-884.
- Nakajima, k., Hata, Y., Osono, Y., Hamura, M., Kobayashi, S., & Watanuki, M. (1995). Antihypertensive effect of extracts of *Lactobacillus casei* in patients

- with hypertension. *Journal of Clinical Biochemistry and Nutrition*, 18, 181-187.
- Neal, G.E., Eaton, D.L., Judah, D.J., & Verma, A. (1998). Metabolism and toxicity of aflatoxins M₁ and B₁ in humanderived in vitro systems. *Toxicology and Applied Pharmacology*, 151, 152-158.
- Oatley, J.T., Rarick, M.D., Ji, G.E., & Linz, J.E. (2000). Binding of aflatoxin B₁ to bifidobacteria *in vitro*. *Journal of Food Protection*, 63, 1133-1136.
- Ohashi, Y., Nakai, S., Tsukamoto, T., Masumori, N., Akaza, H., Miyanaga, N., & et al. (2002). Habitual intake of lactic acid bacteria and risk reduction of bladder cancer. *Urologia internationalis*, 68(4), 273-280.
- Osborne, D., Huff, W., Hamilton, P., & Burtmeister, H. (1982). Comparison of ochratoxin, aflatoxin and T-2 toxin for their effects on selected parameters related to digestion and evidence for specific metabolism of carotenoids in chickens. *Poultry Science*, 61, 1646-1652.
- Parvez, S., Malik, K.A., Ah-Kang, S., & Kim, H.Y. (2006). Probiotics and their fermented food products are beneficial for health. *Journal of Applied Microbiology*, 100(6), 1171-1185.
- Pathmakanthan, S., Meance, S., & Edwards, C.A. (2000). Probiotics: A review of Human Studies to Date and Methodological Approaches. *Microbial Ecology in Health and Disease*, 2, 10-30.
- Peltonen, K., El-Nezami, H., Haskard, C., Ahokas, J., & Salminen, S. (2001). Aflatoxin B₁ binding by dairy strains of *lactic acid bacteria* and *bifidobacteria*. *Journal of Dairy Science*, 84, 2152-2156.
- Peraica, M., Radic, B., Lucic, A., & Pavlovic, M. (1999). Toxic effects of mycotoxins in humans. *Bull World Health Organ*, 77, 754-766.
- Pitt J.I. (2000). Toxigenic fungi and mycotoxins. *British Medical Bulletin*, 56(1), 184-192.
- Ramos, A.J., & Hernández, E. (1996). In situ absorption of aflatoxins in rat small intestine. *Mycopathologia*, 134, 27-30.
- Robbins, C.A. Swenson, L.J. Nealley, M.L. Gots, R.E. & Bruce, J.K. (2000). Health Effects of Mycotoxins in Indoor Air: A Critical Review. *Applied Occupational and Environmental Hygiene*, 15(10), 773-784.
- Robertson, A. (2005). Risk of aflatoxin contamination increases with hot and dry growing conditions. *Integrated Crop Management*, 494, 185-186.
- Roebuck, B.D., & Maxuitenko, Y.Y. (1994). Biochemical mechanisms and biological implications of the toxicity of aflatoxins as related to aflatoxin

carcinogenesis. In D.L. Eaton & J. D. Groopman (Eds.), *The toxicology of aflatoxin* (pp. 27-40). San Diego, California State: Academic Press.

Rojas, M., Ascencio, F., & Conway, P.L. (2002). Purification and characterization of a surface protein from *Lactobacillus fermentum* 104R that binds to porcine small intestinal mucus and gastric mucin. *Apply Environmental Microbiology*, 68, 2330-2336.

Rowland, I.R., & Gangolli, S.D. (1999). Role of Gastrointestinal Microflora in the Metabolic and Toxicological Activities of Xenobiotics. In B. Ballantyne, T.C. Marrs & T. Syverson (Eds.), *General and Applied Toxicology* (pp. 561-575). London: Macmillan References LTD.

Sabbioni, G., Skipper, P.L., Buchi, G., & Tannenbaum, S.R. (1987). Isolation and Characterization of the Major SerumAlbumin Adduct Formed by Aflatoxin B₁ In vivo in Rats. *Carcinogenesis*, 8, 819-824.

Sahagún-Flores, J.E., López-Peña, L.S., Cruz-Ramírez, J.J., García-Bravo, M.S., Peregrina-Gómez, R., & García de Alba-García, J.E. (2007). Eradication of *Helicobacter pylori*: triple treatment scheme plus *Lactobacillus* vs. triple treatment alone. *Latin American Index of Medical Journal*, 74, 333-336.

Salminen, S., Isolauri, E., & Salminen, E. (1996). Clinical uses of probiotics for stabilizing the gut mucosal barrier: successful strains and future challenges. In G. Venema, J.H.J. Huis in't Veld, & J. Hugenholtz (Eds.), *Fifth Symposium on Lactic Acid Bacteria: Genetics, Metabolism and Applications* (pp. 251-262). Veldhoven: Kluwer Academic Publishers.

Salminen, S., Nybom, S., Meriluoto, J., Collado, M.C., Vesterlund, S., & El-Nezami, H. (2010). Interaction of probiotics and pathogens-benefits to human health. *Current Opinion in Biotechnology*, 21, 157-167.

Santosa, S., Farnoworth, E., & Jones, P.J. (2006). Probiotic and their potential health claims. *Nutrition Reviews*, 64(6), 265-274.

Sayed, H.A., Ayyat, A.E., Dusoki, H.E., Zoheiry, M., Mohamed, S., & Hassan, M. (2005). A Cross Sectional Study of Hepatitis B, C, some Trace Elements, Heavy Metals, Aflatoxin B₁ and Schistosomiasis in a Rural Population, Egypt. *The Journal of the Egyptian Public Health Association*, 80, 288-355.

Sherif, S.O., Salama, E.E., & Abdel-Wahhab, M.A. (2009). Mycotoxins and child health: the need for health risk assessment. *International Journal of Hygiene and Environmental Health*, 212(4), 347-368.

Shetty, P., & Jespersen, L. (2006). *Saccharomyces cerevisiae* and lactic acid bacteria as potential mycotoxin decontaminating agents. *Trends Food Science and Technology*, 17(2), 48-55.

- Smela, M.E., Currier, S.S., Bailey, E.A., & Essigmann, J.M. (2001). The chemistry and biology of aflatoxin B₁: From mutational spectrometry to carcinogenesis. *Carcinogenesis*, 22, 535-545.
- Spanhaak, S., Havenaar, R., & Schaafsma, G. (1998). The effect of consumption of milk fermented by *Lactobacillus casei* strain Shirota on the intestinal microflora and immune parameters in humans. *European Journal of Clinical Nutrition*, 52, 899-907.
- Srividya, A.R., & Vishnuvarthan, V.J. (2011). Probiotic: a rational approach to use Probiotic as medicine. *International Journal of Pharmaceutical Frontier Research*, 1, 126-134.
- Styriak, I., & Conkova, E. (2002). Microbial binding and biodegradation of mycotoxins. *Veterinary & Human Toxicology*, 44, 358-361.
- Takahashi, T., Kushiro, A., Nomoto, K., Uchida, K., Morotomi, M., Yokokura, T., & et al. (2001). Antitumoreffects of the intravesical instillation of heat killed cells of the *Lactobacillus casei* strain shirota on the murine orthotopic bladder tumor mbt-2. *The Journal of Urology*, 166(6), 2506-2511.
- Takeda, K., & Okumura, K. (2007). Effects of a fermented milk drink containing *Lactobacillus casei* strain Shirota on the human NK-cell activity. *The Journal of Nutrition*, 137, 791-793.
- Tamura, M., Shikina, T., Morihana, T., Hayama, M., Kajimoto, O., Sakamoto, A., & et al. (2007). Effects of probiotics on allergic rhinitis induced by Japanese cedar pollen: randomized double-blind, placebo-controlled clinical trial. *International Archives of Allergy and Immunology*, 143(1), 75-82.
- Tannock, G.W. (2003). Probiotics: time for a dose of realism. *Current Issues in Intestinal Microbiology*, 4(2), 33-42.
- Tannock, G.W., Munro, K., Harmsen, H.J.M., Welling, G.W., Smart, J. & Gopal, P.K. (2000). Analysis of the Fecal Microflora of Human Subjects Consuming a Probiotic Product Containing *Lactobacillus rhamnosus* DR20. *Applied and Environmental Microbiology*, 66(6), 2578-2588.
- Taranto, M.P., Medici, M., Perdigon, G., Ruiz-Holgado, A.P., & Valdez, G.F. (2000). Effect of *Lactobacillus reuteri* on the prevention of hypercholesterolemia in mice. *Journal of Dairy Science*, 83, 401-403.
- Terahara, M., Meguro, S., & Kaneko, T. (1998). Effects of lactic acid bacteria on binding and absorption of mutagenic heterocyclic amines. *Bioscience Biotechnology Biochemistry*, 62, 197-200.
- Thyagaraja, N., & Hosono, A. (1994). Binding properties of lactic acid bacteria from 'Idly' towards foodborne mutagens. *Food Chemistry and Toxicology*, 32, 805-809.

- Tuomola, E.M., Ouwehand, A.C., & Salminen, S.J. (2000). Chemical, physical and enzymatic pretreatments of probiotic lactobacilli alter their adhesion to human intestinal mucus glycoproteins. *International Journal of Food Microbiology*, *60*, 75-81.
- Turbic, A., Ahokas, J.T., & Haskard, C.A. (2002). Selective in vitro binding of dietary mutagens, individually or in combination, by lactic acid bacteria. *Food Additives and Contaminants*, *19*, 144-152.
- Turnbaugh, P.J., Ley, R.E., Mahowald, M.A., Magrini, V., Mardis, E.R. & Gordon, J.I. (2006). An obesity-associated gut microbiome with increased capacity for energy harvest. *International Weekly Journal of Science*, *444*(7122), 1027-1031.
- Turner, P.C., Moore, S.E., Hall, A.J., Prentice, A.M., & Wild, C.P. (2003). Modification of immune function through exposure to dietary aflatoxin in Gambian children. *Environmental Health Perspectives*, *111*, 217-220.
- Ueng, Y.F., Shimada, T., Yamazaki, H., & Guengerich, F.P. (1995). Oxidation of aflatoxin B₁ by bacterial recombinant human cytochrome P450 enzymes. *Chemical Research in Toxicology*, *8*, 218-225.
- Valeur, N., Engel, P., Carbajal, N., Connolly, E., & Ladefoged, K. (2004). Colonization and immunomodulation by *Lactobacillus reuteri* ATCC 55730 in the human gastrointestinal tract. *Applied and Environmental Microbiology*, *70*, 1176-1181.
- Van Vleet, T.R., Klein, P.J., & Coulombe, R.A. (2001). Metabolism of aflatoxin B₁ by normal human bronchial epithelial cells. *Journal of Toxicology and Environmental Health Part A*, *63*, 525-540.
- Vermeulen, N. (1996). Role of metabolism in chemical toxicology. In C. Ioannides (Eds.), *Cytochrome P450: Metabolic and toxicological aspects* (pp. 29-53). Boca Raton: CRC Press Inc.
- Wild, C.P. & Gong, Y.Y. (2010). Mycotoxins and human disease: a largely ignored global health issue. *Carcinogenesis*, *31*(1), 71-82.
- Williams, J.H., Phillips, T.D., Jolly, P.E., Stiles, J.K., Jolly, C.M., & Aggarwal, D. (2004). Human aflatoxicosis in developing countries: a review of toxicology, exposure, potential health consequences, and interventions. *American Journal of Clinical Nutrition*, *80*(5), 1106-1122.
- Yakult. (n.d.). In *Wikipedia*. Retrieved Desember 17, 2011, from <http://en.wikipedia.org/wiki/Yakult>
- Yamazaki, K., Tsunoda, A., Sibusawa, M., Tsunoda, Y., Kusano, M., Fukuchi, K., & et al. (2000). The effect of an oral administration of *Lactobacillus casei* strain shirota on azoxymethane-induced colonic aberrant crypt foci and colon cancer in the rat. *Oncology Reports*, *7*(5), 977-982.

Yuan, S.S., Tsai, K.B., Chung, Y.F., Vhan, T.F., Yeh, Y.T., Tsai, L.Y., & et al. (2004). Aberrant expression and possible involvement of the leptin receptor in endometrial cancer. *Gynecologic Oncology*, 92, 769-775.

Zareie, M., Johnson-Henry, K., Jury, J., Yang, P.C., Ngan, B.Y., McKay, D.M., & et al. (2006). Probiotics prevent bacterial translocation and improve intestinal barrier function in rats following chronic psychological stress. *International Journal in Gastroenterology and Hepatology*, 55(11), 1553-1560.

Zsivkovits, M., Fekadu, K., Sontag, G., Nabinger, U., Huber, W.W., Kundi M., & et al. (2003). Prevention of heterocyclic amine-induced DNA damage in colon and liver of rats by different lactobacillus strains. *Carcinogenesis*, 24, 1913-1918.

